Scarica l'app Stockscreener
15.89
4.20%
0.64
Precedente Chiudi:
$15.25
Aprire:
$15.42
Volume 24 ore:
213.00K
Relative Volume:
0.39
Capitalizzazione di mercato:
$959.77M
Reddito:
$1.23M
Utile/perdita netta:
$-214.90M
Rapporto P/E:
-3.8547
EPS:
-4.1222
Flusso di cassa netto:
$-151.25M
1 W Prestazione:
-5.81%
1M Prestazione:
+1.27%
6M Prestazione:
-31.71%
1 anno Prestazione:
-34.64%
Intervallo 1D:
$15.31
$15.93
Intervallo di 1 settimana:
$14.72
$16.88
Portata 52W:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.89 | 921.11M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Real time scanner hits for Spyre Therapeutics Inc. explainedAI Risk Optimized Trade Forecast Planner - Newser
Is Spyre Therapeutics Inc. forming a bottoming baseFree Breakout Entry Signal Confirmation Tool - Newser
Using flow based indicators on Spyre Therapeutics Inc.Daily Trade Monitor with Pattern Alerts - Newser
Will Spyre Therapeutics Inc. rebound enough to break evenPrice Spike Prediction for Active Traders - Newser
Is now a turning point for Spyre Therapeutics Inc.Machine Learning Stock Price Forecast Tool - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser
Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsChart Signal and Short-Term Forecast Tracker - Newser
What institutional flow reveals about Spyre Therapeutics Inc.Short-Term Profit Alert With Entry Forecast - Newser
Using AI based signals to follow Spyre Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser
How Spyre Therapeutics Inc. stock performs during market volatilityFree Low Risk High Return Opportunities - Newser
What data driven models say about Spyre Therapeutics Inc.’s futureFree AI Driven Buy Alert Trade Blueprint - Newser
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
What’s the recovery path for long term holders of Spyre Therapeutics Inc.Daily Trade Setup Forecast with Confidence - Newser
Spyre Therapeutics Inc. Consolidation Zone May Signal AccumulationBreakout Momentum Picks With Protection Outlined - beatles.ru
Spyre Therapeutics Inc.’s volatility index tracking explainedFree AI Trading Suggestions With Accuracy Focus - Newser
What moving averages say about Spyre Therapeutics Inc.Future Growth Stock Forecasting Strategy - Newser
Will a bounce in Spyre Therapeutics Inc. offer an exitChart Confirmation Setup with ROI Signals - Newser
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionWeekly Growth Portfolio Performance Summary - Newser
Applying sector rotation models to Spyre Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Can Spyre Therapeutics Inc. expand its profit marginsFree Trading Community Access - thegnnews.com
Can momentum traders help lift Spyre Therapeutics Inc.Free Weekly Chart Analysis With Entry Advice - Newser
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows - Nasdaq
Stifel reiterates Buy rating on Spyre stock with $71 price target - Investing.com Canada
Spyre Therapeutics: Q2 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q2 2025 Financial Results - TipRanks
Visual trend scoring systems applied to Spyre Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Spyre Therapeutics: A Biotech Turnaround Story? Evaluating Operational Efficiency and Earnings Resilience in a High-Risk Sector - AInvest
Spyre Therapeutics's 15min chart sees KDJ Golden Cross, Bullish Marubozu pattern confirmed. - AInvest
Market reaction to Spyre Therapeutics Inc.’s recent newsTechnical Reversal Pattern Summary and Tracker - Newser
Spyre Therapeutics Inc. Uptrend in Early Stages Indicators Say YesDaily Smart Money Movement Monitor Activated - beatles.ru
Moving Average Trends for Spyre Therapeutics Inc. Stock: What They IndicateTechnical Long-Term Outlook and Recap Guide - Newser
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):